{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:29:52Z","timestamp":1793816992816,"version":"4.6.1"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is a well-recognized entity with specific characteristics. Previously considered inoperable, these tumors are now increasingly resectable due to advances in neoadjuvant chemotherapy. This review synthesizes current knowledge on diagnostic, therapeutic, and management approaches for pancreatic ductal adenocarcinoma, especially for BR disease. It covers the definition, criteria, and surgical management, along with various clinical challenges in the diagnosis of borderline disease. Neoadjuvant therapy is the treatment of choice before surgery, but there are still limited data on the selection of optimal therapy and on the early identification of non-responders. Multidetector computed tomography, along with CA19-9 and positron emission tomography, are being used to evaluate resectability after neoadjuvant therapy. Pancreatic resection for PDAC is one of the most complex procedures in abdominal surgery due to the technical and oncological challenges associated with its aggressive growth. Despite these options, management remains challenging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005565","type":"journal-article","created":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:01:15Z","timestamp":1793815275000},"page":"6654-6661","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Borderline resectable pancreatic ductal adenocarcinoma: a narrative review"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4874-0720","authenticated-orcid":false,"given":"Rupesh","family":"Thapa Chhetri","sequence":"first","affiliation":[{"name":"Department of General Surgery, National Medical College, Birgunj, Parsa, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisha","family":"Maharjan","sequence":"additional","affiliation":[{"name":"Department of Surgical Gastroenterology, Kist Medical College, Lalitpur, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"752\u201365","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"2008\u201320","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"10732748231153094","DOI":"10.1177\/10732748231153094","article-title":"Surgical treatment of pancreatic cancer: currently debated topics on vascular resection","volume":"30","author":"Pedrazzoli","year":"2023","journal-title":"Cancer Control"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"731\u201346","DOI":"10.1016\/j.soc.2021.06.011","article-title":"Pancreaticoduodenectomy and vascular reconstruction","volume":"30","author":"Christians","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"R6-20261104","first-page":"755\u201368","article-title":"Japanese classification of pancreatic carcinoma by the Japan pancreas society: eighth edition","volume":"31","author":"Ishida","year":"2024","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"2\u201311","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"2325\u201336","DOI":"10.1245\/s10434-020-09100-6","article-title":"Impact of borderline resectability in pancreatic head cancer on patient survival: biology matters according to the new international consensus criteria","volume":"28","author":"Anger","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"703\u201313","DOI":"10.6004\/jnccn.2012.0073","article-title":"Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines","volume":"10","author":"Tempero","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"2306\u201314","DOI":"10.1007\/s00268-015-3096-3","article-title":"National comprehensive cancer network resectability status for pancreatic carcinoma predicts overall survival","volume":"39","author":"Murakami","year":"2015","journal-title":"World J Surg"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1097\/MD.0000000000001647","article-title":"Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment","volume":"94","author":"Fujii","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R12-20261104","first-page":"143\u201355","article-title":"Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery","volume":"28","author":"Inoue","year":"2021","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"833\u201346","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"413\u201320","DOI":"10.1080\/02841860701592384","article-title":"Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma","volume":"47","author":"Lind","year":"2008","journal-title":"Acta Oncol"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"315\u201320","DOI":"10.1002\/jso.21469","article-title":"Neoadjuvant therapy for pancreatic cancer: a current review","volume":"101","author":"Abbott","year":"2010","journal-title":"J Surg Oncol"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"28\u201337","DOI":"10.1016\/j.pan.2015.11.007","article-title":"Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"16","author":"Tang","year":"2016","journal-title":"Pancreatology"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"202\u201310","DOI":"10.6004\/jnccn.2019.0014","article-title":"Guidelines insights: pancreatic adenocarcinoma, version 1.2019","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"987\u20131002","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"R19-20261104","first-page":"1\u201315","article-title":"Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis","volume":"76","author":"Yang","year":"2024","journal-title":"Updat Surg"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"157\u201368","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"215\u201322","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"S1323","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83 neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial","volume":"34","author":"Groot Koerkamp","year":"2023","journal-title":"Ann Oncol"},{"key":"R24-20261104","first-page":"4621\u201333","article-title":"Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015)","volume":"31","author":"Yamada","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"1346\u201356","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"1043\u201349","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"343\u201349","DOI":"10.1148\/radiol.2019190422","article-title":"Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement","volume":"293","author":"Joo","year":"2019","journal-title":"Radiology"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"12\u201317","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"806\u201313","DOI":"10.1097\/SLA.0000000000003442","article-title":"Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer","volume":"273","author":"Perri","year":"2021","journal-title":"Ann Surg"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40644-023-00528-z","article-title":"Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Imaging"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"42\u201353","DOI":"10.1016\/j.jss.2022.10.008","article-title":"Innovative imaging techniques used to evaluate borderline-resectable pancreatic adenocarcinoma","volume":"284","author":"Chalfant","year":"2023","journal-title":"J Surg Res"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"151\u201358","DOI":"10.1097\/SLA.0000000000004915","article-title":"Surgical decision-making in pancreatic ductal adenocarcinoma: modeling prognosis following pancreatectomy in the era of induction and neoadjuvant chemotherapy","volume":"277","author":"Habib","year":"2023","journal-title":"Ann Surg"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"394\u2013404","DOI":"10.1097\/PAS.0000000000001601","article-title":"A critical assessment of postneoadjuvant therapy pancreatic cancer regression grading schemes with a proposal for a novel approach","volume":"45","author":"Chou","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R34-20261104","doi-asserted-by":"crossref","first-page":"627\u201339","DOI":"10.1016\/j.ijrobp.2022.12.039","article-title":"Vasculitis, CA19-9, and perineural invasion differentially predict response and surgical outcome in pancreatic ductal adenocarcinoma","volume":"116","author":"Piper","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"R35-20261104","doi-asserted-by":"crossref","first-page":"839339","DOI":"10.3389\/fsurg.2022.839339","article-title":"Short-course or total neoadjuvant chemotherapy in resectable and borderline resectable pancreatic cancer - current status and future perspectives","volume":"9","author":"Labori","year":"2022","journal-title":"Front Surg"},{"key":"R36-20261104","doi-asserted-by":"crossref","first-page":"333\u201343","DOI":"10.1007\/s10565-019-09465-9","article-title":"Proteomic and genomic profiling of pancreatic cancer","volume":"35","author":"Ansari","year":"2019","journal-title":"Cell Biol Toxicol"},{"key":"R37-20261104","doi-asserted-by":"crossref","first-page":"100\u201308","DOI":"10.1016\/j.hpb.2022.09.012","article-title":"Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels","volume":"25","author":"Ono","year":"2023","journal-title":"HPB"},{"key":"R38-20261104","doi-asserted-by":"crossref","first-page":"341\u201349","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"R39-20261104","doi-asserted-by":"crossref","first-page":"605\u201311","DOI":"10.1016\/j.hpb.2018.01.001","article-title":"Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy","volume":"20","author":"Van veldhuisen","year":"2018","journal-title":"HPB"},{"key":"R40-20261104","doi-asserted-by":"crossref","first-page":"30\u201330","DOI":"10.21037\/cco-22-49","article-title":"Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review","volume":"11","author":"Valukas","year":"2022","journal-title":"Chin Clin Oncol"},{"key":"R41-20261104","doi-asserted-by":"crossref","first-page":"596\u2013601","DOI":"10.1097\/00006231-199307000-00013","article-title":"Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results","volume":"14","author":"Bares","year":"1993","journal-title":"Nucl Med Commun"},{"key":"R42-20261104","doi-asserted-by":"crossref","first-page":"493\u2013511","DOI":"10.1007\/s10147-023-02317-x","article-title":"Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis","volume":"28","author":"Okusaka","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"R43-20261104","first-page":"1768\u201378","article-title":"The value of 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance whole-body scans and local enhancement scans in the preoperative staging and resectability assessment of pancreatic adenocarcinoma","volume":"13","author":"Wang","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"R44-20261104","doi-asserted-by":"crossref","first-page":"790462","DOI":"10.3389\/fonc.2021.790462","article-title":"Pretherapeutic assessment of pancreatic cancer: comparison of FDG PET\/CT plus delayed PET\/MR and contrast-enhanced CT\/MR","volume":"11","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"R45-20261104","doi-asserted-by":"crossref","first-page":"49\u201357","DOI":"10.1097\/XCS.0000000000000704","article-title":"Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of more than 1,000 consecutive patients","volume":"237","author":"Gudmundsdottir","year":"2023","journal-title":"J Am Coll Surg"},{"key":"R46-20261104","doi-asserted-by":"crossref","first-page":"722\u201335","DOI":"10.1136\/gutjnl-2021-326610","article-title":"SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer","volume":"72","author":"Rapetti-mauss","year":"2023","journal-title":"Gut"},{"key":"R47-20261104","doi-asserted-by":"crossref","first-page":"100960","DOI":"10.1016\/j.drup.2023.100960","article-title":"Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs","volume":"68","author":"Qi","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R48-20261104","doi-asserted-by":"crossref","first-page":"386\u201394","DOI":"10.2967\/jnumed.122.264544","article-title":"PET imaging of fibroblast activation protein in various types of cancer using68Ga-FAP-2286: comparison with18 F-FDG and68Ga-FAPI-46 in a single-center, prospective study","volume":"64","author":"Pang","year":"2023","journal-title":"J Nucl Med"},{"key":"R49-20261104","first-page":"5007\u201316","article-title":"The added value of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in pancreatic cancer: a comparison to [18F]F-FDG","volume":"33","author":"Liu","year":"2023","journal-title":"Eur Radiol"},{"key":"R50-20261104","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.3390\/cancers13236088","article-title":"Overview and future perspectives on tumor-targeted positron emission tomography and fluorescence imaging of pancreatic cancer in the era of neoadjuvant therapy","volume":"13","author":"Van Dam","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R51-20261104","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.3390\/cancers13246164","article-title":"Molecular targeted positron emission tomography imaging and radionuclide therapy of pancreatic ductal adenocarcinoma","volume":"13","author":"Poels","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R52-20261104","doi-asserted-by":"crossref","first-page":"559\u201370","DOI":"10.1016\/S2468-1253(19)30081-0","article-title":"Molecular radionuclide imaging of pancreatic neoplasms","volume":"4","author":"Panda","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R53-20261104","doi-asserted-by":"crossref","first-page":"443\u201350","DOI":"10.1007\/s00423-021-02362-y","article-title":"State-of-the-art surgery for pancreatic cancer","volume":"407","author":"Nie\u00dfen","year":"2022","journal-title":"Langenbecks Arch Surg"},{"key":"R54-20261104","first-page":"17\u201322","article-title":"Developments in pancreatic cancer surgery","volume":"76","author":"Shah","year":"2024","journal-title":"Updat Surg"},{"key":"R55-20261104","doi-asserted-by":"crossref","first-page":"3014\u201323","DOI":"10.1007\/s11605-023-05848-w","article-title":"Surgical planning for \u201cborderline resectable\u201d and \u201clocally advanced\u201d pancreatic cancer during open pancreatic resection","volume":"27","author":"Tamburrino","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"R56-20261104","doi-asserted-by":"crossref","first-page":"3184\u201385","DOI":"10.1245\/s10434-023-13271-3","article-title":"Editorial on: moving beyond anatomic criteria for resectability: validation of the anatomical and biological definitions of borderline resectable pancreatic cancer according to the 2017 international consensus for survival and recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfront surgery","volume":"30","author":"Paniccia","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R57-20261104","doi-asserted-by":"crossref","first-page":"1443\u201350","DOI":"10.1002\/bjs.10662","article-title":"Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours","volume":"104","author":"Palanivelu","year":"2017","journal-title":"Br J Surg"},{"key":"R58-20261104","doi-asserted-by":"crossref","first-page":"731\u201339","DOI":"10.1097\/SLA.0000000000002893","article-title":"Comparison of perioperative outcomes between laparoscopic and open approach for pancreatoduodenectomy: the PADULAP randomized controlled trial","volume":"268","author":"Poves","year":"2018","journal-title":"Ann Surg"},{"key":"R59-20261104","doi-asserted-by":"crossref","first-page":"199\u2013207","DOI":"10.1016\/S2468-1253(19)30004-4","article-title":"Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2\/3 trial","volume":"4","author":"Van Hilst","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R60-20261104","doi-asserted-by":"crossref","first-page":"23\u201332","DOI":"10.1002\/jso.27240","article-title":"Does minimally invasive surgery have a different impact on recurrence and overall survival in patients with pancreatic head versus body\/tail cancer?","volume":"128","author":"Choi","year":"2023","journal-title":"J Surg Oncol"},{"key":"R61-20261104","doi-asserted-by":"crossref","first-page":"6096\u2013109","DOI":"10.3390\/curroncol31100455","article-title":"Oncological outcomes of open versus minimally invasive surgery for ductal adenocarcinomas of pancreatic head: a propensity score matching analysis","volume":"31","author":"Giani","year":"2024","journal-title":"Curr Oncol"},{"key":"R62-20261104","doi-asserted-by":"crossref","first-page":"575\u201386","DOI":"10.1016\/j.hpb.2020.08.016","article-title":"Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma","volume":"23","author":"Pu","year":"2021","journal-title":"HPB"},{"key":"R63-20261104","doi-asserted-by":"crossref","first-page":"1052\u201359","DOI":"10.1097\/SLA.0000000000006295","article-title":"Defining the minimal and optimal thresholds for lymph node resection and examination for intraductal papillary mucinous neoplasm\u2013derived pancreatic cancer: a multicenter retrospective analysis","volume":"282","author":"Habib","year":"2025","journal-title":"Ann Surg"},{"key":"R64-20261104","doi-asserted-by":"crossref","first-page":"2082\u201388","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"key":"R65-20261104","doi-asserted-by":"crossref","first-page":"2751\u201359","DOI":"10.1007\/s00268-022-06667-x","article-title":"Postoperative chemotherapy is associated with improved survival in patients with node-positive pancreatic ductal adenocarcinoma after neoadjuvant therapy","volume":"46","author":"Ivey","year":"2022","journal-title":"World J Surg"},{"key":"R66-20261104","doi-asserted-by":"crossref","first-page":"1196\u2013205","DOI":"10.1245\/s10434-015-4783-x","article-title":"Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEO-FRENCH, prospective, multicentric cohort","volume":"22","author":"Pietrasz","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R67-20261104","doi-asserted-by":"crossref","first-page":"1793\u2013803","DOI":"10.1007\/s11605-017-3544-5","article-title":"Is adjuvant therapy necessary for all patients with localized pancreatic cancer who have received neoadjuvant therapy?","volume":"21","author":"Barnes","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"R68-20261104","doi-asserted-by":"crossref","first-page":"6482\u201385","DOI":"10.1097\/JS9.0000000000002729","article-title":"Mental health and surgery: integrating psychological care into surgical treatment plans: letter to editor","volume":"111","author":"Hsu","year":"2025","journal-title":"Int J Surg"},{"key":"R69-20261104","doi-asserted-by":"crossref","first-page":"542\u201348","DOI":"10.1097\/SLA.0000000000006213","article-title":"Mindfulness-based interventions for surgeons: a scoping review","volume":"281","author":"Coopersmith","year":"2025","journal-title":"Ann Surg"},{"key":"R70-20261104","doi-asserted-by":"crossref","first-page":"464\u201370","DOI":"10.3109\/00365521.2010.539256","article-title":"A prediction rule for estimating pancreatic cancer risk in chronic pancreatitis patients with focal pancreatic mass lesions with prior negative EUS-FNA cytology","volume":"46","author":"Cai","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"R71-20261104","doi-asserted-by":"crossref","first-page":"19\u201330","DOI":"10.1016\/j.ejca.2020.10.019","article-title":"Development and validation of a pancreatic cancer risk model for the general population using electronic health records: an observational study","volume":"143","author":"Appelbaum","year":"2021","journal-title":"Eur J Cancer"},{"key":"R72-20261104","doi-asserted-by":"crossref","first-page":"582864","DOI":"10.3389\/fcell.2020.582864","article-title":"Early diagnosis of pancreatic ductal adenocarcinoma by combining relative expression orderings with machine-learning method","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"R73-20261104","first-page":"2795\u2013803","article-title":"Establishment and application of an artificial intelligence diagnosis system for pancreatic cancer with a faster region-based convolutional neural network","volume":"132","author":"Liu","year":"2019","journal-title":"Chin Med J (Engl)"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:01:24Z","timestamp":1793815284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005565","relation":{},"ISSN":["2049-0801","2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"},{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2026-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}